GT Biopharma, Inc.
GTBP· Nasdaq
GTBPGT Biopharma, Inc.
Filed Mar 2, 2026 · 10-K · 61 days after period end · 0001493152-26-008443
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$5.71M | -$3.78M | -$2.96M | -$5.58M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
ended Dec 31, 2025 · filed Mar 2, 2026 · 61 d after period end
